Background

Dengue is a viral disease transmitted mainly by Aedes mosquitoes, with four described serotypes and wide circulation in tropical and subtropical regions.

The infection can range from mild, nonspecific febrile illness to severe forms, especially in secondary infections or in patients with risk factors. Therefore, diagnosis at the right time is essential.

Chemiluminescence tests for IgM and IgG antibodies are a suitable serological solution for dengue, due to their sensitivity, automation, and ability to integrate into routine sample processing.

Dengue VirClia

Product features

Chemiluminescent immunoassays (CLIA) to test antibodies against dengue virus in human serum or plasma samples.

  • Monotest format with ready-to-use reagents.
  • Highly specific IgM immunocapture method.
  • Simple and automated protocol, with fast results.
  • Customizable configuration of samples and reagents according to laboratory needs.
  • Each monotest includes a calibrator and a negative control, enabling individual validation and interpretation of each sample.
  • Use of primary tubes, with no need for manual pipetting.
virclia monotest

PRODUCTS

DENGUE VIRCLIA® IgG MONOTEST

CE
Indirect chemiluminescent immunoassay (CLIA) to test IgG antibodies against dengue virus in human serum/plasma.

Analytes: Dengue

Reference VCM023
Pack size 24 test

DENGUE VIRCLIA® IgM MONOTEST

CE
Capture chemiluminescent immunoassay (CLIA) to test IgM antibodies against dengue virus in human serum/plasma.

Analytes: Dengue

Reference VCM024
Pack size 24 test

USED ON

VIRCLIA® LOTUS

virclia_lotus.jpeg

A compact automated CLIA platform for VirClia® infectious disease testing, combining ready-to-use single-test flexibility with continuous random access efficiency.

MORE RESOURCES

Virus/Bacterias
RELATED VIRUSES/BACTERIA

Related germs and organisms categorized for this product line.

Flyers
FLYERS

Downloadable PDF materials, brochures, and technical documents.

Blog
BLOG

The latest insights, news, and research articles from our scientific team.

Measles in the Americas in 2026: strengthening laboratory diagnosis amid rising cases
21 October 2026

Measles in the Americas in 2026: strengthening laboratory diagnosis amid rising cases

Measles is once again a major public health concern across the Americas.After years of progress towards elimination, measles has made a significant co...

H. pylori stool antigen testing: when the test works, but the workflow no longer does
21 September 2026

H. pylori stool antigen testing: when the test works, but the workflow no longer does

Helicobacter pylori stool antigen testing is an established non-invasive approach for detecting active H. pylori infection. Validated monoclonal stool...

Polymicrobial Vaginal Infections: why third-party controls matter in molecular testing
10 August 2026

Polymicrobial Vaginal Infections: why third-party controls matter in molecular testing

Understanding the complexity of vaginal infectionsVaginal infections are among the most frequent reasons for gynecological consultation, but their dia...

Bibliography
BIBLIOGRAPHY

Scientific bibliography and references related to this product.

Centre National de Référence des Arbovirus, CHI Toulon. VIRCLIA® IgG IgM MONOTEST DENV. Toulon: Centre National de Référence des Arbovirus; 2023.
Guigon A, Coulon P, Pezzi L, Regueme A, Debuysschere C, Lazrek M, et al. Evaluation of a Fully Automated Assay for Detection of Antidengue IgM Antibodies in a Nonendemic Area. Journal of Tropical Medicine. 2025 Jan;2025(1).